Mercado mundial de medicamentos contra la osteoporosis: tendencias de la industria y pronóstico hasta 2030

Análisis y tamaño del mercado de medicamentos contra la osteoporosis

El mercado mundial de medicamentos contra la osteoporosis está experimentando un crecimiento constante impulsado por factores como el envejecimiento de la población, la creciente prevalencia de la osteoporosis y la creciente conciencia sobre la salud ósea. Data Bridge Market Research analiza que el mercado de medicamentos contra la osteoporosis, que fue de USD 15.576,30 millones en 2022, se disparará hasta USD 20.332,57 millones para 2030, y se espera que experimente una CAGR del 4,68% durante el período de pronóstico. Esto indica que el valor de mercado. "Medicamentos" domina el segmento de tipo de tratamiento del mercado de medicamentos contra la osteoporosis debido a la creciente demanda de tratamiento con medicamentos debido al aumento de la prevalencia de la osteoporosis a nivel mundial. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de medicamentos contra la osteoporosis

Market Definition

Osteoporosis is a condition of bone weakening or bones becomes fragile and likely to break. In other words, osteoporosis is a condition wherein the bone density decreases. This is specially witnessed in old age people. Osteoporosis brings along back pain, stooped posture, bone fracture and tooth loss.

Osteoporosis Drug Market Dynamics

Drivers

• Increasing Prevalence of Osteoporosis

The prevalence of osteoporosis is increasing worldwide mainly due to changing lifestyles, poor diet and sedentary lifestyle. Factors that contribute to osteoporosis, such as reduced physical activity, insufficient intake of calcium and vitamin D and hormonal imbalances. The increasing number of people suffering from osteoporosis is creating a significant demand for osteoporosis drugs

• Increased Awareness and Diagnosis

Awareness of osteoporosis and its consequences has increased significantly among both health professionals and the general public. Initiatives by health organizations, patient advocacy groups, and pharmaceutical companies have played an important role in educating people about osteoporosis prevention, early detection, and available treatment options. As a result, more and more people are diagnosed with osteoporosis, increasing the demand for osteoporosis drugs

• Technological Advances in Drug Development

Technological advances in drug development have made it possible to discover and develop more effective and targeted treatments for osteoporosis. The use of advanced imaging techniques, molecular biology and genomics has provided insight into the pathophysiology of osteoporosis and led to the identification of new drug targets. The development of new drug delivery systems and formulation techniques will also improve the efficacy and patient compliance of osteoporosis medications 

• Growing Investment for Healthcare Facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities

Opportunities

• Targeted Therapies and Personalized Medicine

The development of targeted therapies and personalized treatment approaches offers the opportunity to improve the effectiveness and safety of osteoporosis treatment. Advances in genomics, biomarker identification and precision medicine enable specific patient subgroups that may benefit from tailored treatment. By developing innovative treatment methods that meet the individual characteristics and needs of the patient, treatment results can be improved and products can be differentiated in the market 

• Research and Development for New Drug Candidates

Ongoing research and development in the field of osteoporosis offers opportunities for the discovery and development of new drug candidates. Exploring new mechanisms of action, identifying innovative drug targets and exploiting advances in drug delivery systems can lead to the development of innovative therapies with greater efficacy and fewer side effects. Companies that invest in RandD to expand their product portfolio can take advantage of these opportunities and gain a competitive advantage in the market 

Restraints

• Patent Expiration and Generic Competition

Many osteoporosis drugs have had patent expirations, allowing generic versions to enter the market. Generic drug competition often leads to lower prices, which reduces the revenue potential of originator drug manufacturers. This may affect profitability and hinder the growth of the osteoporosis drug market 

• Side Effects and Safety Concerns

Osteoporosis medications, such as all medications, can have potential side effects and safety concerns. Some medications have been associated with rare but serious side effects, such as atypical fractures and osteonecrosis of the jaw. These safety concerns may lead to regulatory actions, warnings, and restrictions affecting the prescribing and marketing of certain osteoporosis drugs

Challenges

• High Development Costs and Long Development Times

Developing and marketing a new osteoporosis drug requires significant research and development costs, including preclinical studies, clinical trials and regulatory notifications. The process can be time-consuming and often takes years from initial discovery to commercialization. In addition, the high failure rate of clinical trials further increases costs and lengthens development schedules. These challenges increase the financial burden on pharmaceutical companies and create uncertainty about the return on invested capital 

• Reimbursement and Pricing Pressures

Osteoporosis drugs, especially the newer biologics, can be expensive. Pricing pressures from health systems, payers and insurance companies can limit the availability and affordability of these drugs. Reimbursement policies, formulary restrictions, and cost containment measures can affect market access, patient affordability, and overall market demand. Pharmaceutical companies must overcome these challenges to secure favourable reimbursement and pricing agreements while demonstrating the value and cost-effectiveness of their products 

This osteoporosis drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Osteoporosis Drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Recent Developments

• In August 2021, Enzene Biosciences Ltd received Marketing Authorization (MA) from the Drug Controller General of India (DCGI) for its biosimilar drug, denosumab, indicated for the treatment of osteoporosis in adults
• In January 2021, Theramex, a London-headquartered pharmaceutical company, launched the osteoporosis medicine Livogiva in Europe

Global Osteoporosis Drug Market Scope

The osteoporosis drug market is segmented on the basis of type, therapy type, treatment type, mechanism of action, route of administration and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Primary osteoporosis
• Postmenopausal osteoporosis
• Senile osteoporosis
• Idiopathic osteoporosis
• Seocndary osteoporosis

Therapy type

• Hormone Replacement Therapy​​​​​​​
• Testosterone Replacement Therapy
• Estrogen Therapy
• Bisphosphonate Therapy

Treatment type

• Medication
• Calcium
• Vitamin D Supplements
• Antacids
• Surgery
• Vertebroplasty
• Kyphoplasty
• Others

Mechanism of Action

• Bisphosphonates
• Alendronate
• Ibandronate
• Risedronate
• Zoledronic
• Selective Estrogen Receptor Modulators
• Raloxifene
• Bone Resorption Inhibitors
• Denosumab

Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Others

End-User

• Hospitals
• Homecare
• Specialty clinics
• Others

Osteoporosis Drug Market Regional Analysis/Insights

The osteoporosis drug market is analysed and market size insights and trends are provided by country, type, therapy type, treatment type, mechanism of action, route of administration and end-users as referenced above.

The countries covered in the osteoporosis drug market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the osteoporosis drug market owing to the easy availability of osteoporosis drugs and rising prevalence of osteoporosis.   

Asia-Pacific is projected to score highest growth rate for the forecast period owing to rising expenditure to develop healthcare infrastructure coupled with growth and expansion of life sciences industry.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The Osteoporosis drug market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Osteoporosis drug market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Osteoporosis Drug market. The data is available for historic period from 2021 to 2030.

Competitive Landscape and Osteoporosis Drug Market Share Analysis

The osteoporosis drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to osteoporosis drug market.

Some of the major players operating in the osteoporosis drug market are

• GlaxoSmithKline plc. (U.K.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Eli Lilly And Company. (U.S.)
• Astrazeneca (U.K.)
• Pfizer Inc. (U.S.)
• Takeda Pharmaceutical Company Limited. (Japan)
• Compañía Bristol-Myers Squibb (Estados Unidos)
• Sanofi (Francia)
• Johnson & Johnson Services, Inc. (Estados Unidos)
• Bayer AG (Alemania)
• AbbVie Inc. (Estados Unidos)
• Allergan (Irlanda)
• Merck & Co., Inc. (Estados Unidos)
• Amgen Inc. (Estados Unidos)
• Industrias farmacéuticas Sun Ltd. (India)
• Industrias farmacéuticas Teva Ltd. (Israel)
• Novo Nordisk A/S (Dinamarca)
• DAIICHI SANKYO COMPANY (Japón), LIMITADA.
• Cipla Inc. (India)

SKU-42545